United States of America

Population 2018  327 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>9.8 (8.4–11)</td>
<td>3 (2.6–3.5)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.5 (0.42–0.6)</td>
<td>0.15 (0.13–0.18)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>0.21 (0.16–0.27)</td>
<td>0.07 (0.05–0.08)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.58 (0.57–0.59)</td>
<td>0.18 (0.17–0.18)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.077 (0.05–0.11)</td>
<td>0.02 (0.02–0.03)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases 1.5% (1.2–1.9)
- Previously treated cases 7.4% (4.5–12)

TB case notifications, 2018
- Total new and relapse 8 561
  - % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status 87%
  - % pulmonary 79%
  - % bacteriologically confirmed** 86%
  - % children aged 0–14 years 4%
  - % women 37%
  - % men 59%
- Total cases notified 8 977

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018 87% (75–100)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018 7% (6–8)
- TB/HIV care in new and relapse TB patients, 2018
  - Number (%)
  - Patients with known HIV status who are HIV-positive 381 5%
    - on antiretroviral therapy

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance***
  - New cases
  - Previously treated cases 81%
- Laboratory-confirmed cases* MDR/RR-TB: 111, XDR-TB: 1
- Patients started on treatment* ** MDR/RR-TB: 106, XDR-TB: 1
- MDR/RR-TB cases tested for resistance to second-line drugs 87

Treatment success rate and cohort size
- New and relapse cases registered in 2017 77% 8 536
- Previously treated cases, excluding relapse, registered in 2017 76% 401
- HIV-positive TB cases registered in 2017 68% 403
- MDR/RR-TB cases started on second-line treatment in 2016 69% 111
- XDR-TB cases started on second-line treatment in 2016 100% 1

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019
- National TB budget (US$ millions) 135

*Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-20